Publication Brief
The ability to measure oncology biomarkers at ultra-low levels using Simoa® technology holds great promise for cancer research and clinical practice. Simoa® immunoassays can potentially serve as tools aiding in a range of critical functions in oncology, from early detection and risk assessment to distinguishing between benign and malignant tumors. Additionally, oncology biomarkers also have the potential to be used prognostically, providing insights into disease outcomes and progression-free survival, while also facilitating the monitoring of cancer recurrence and sensitivity to therapy. In essence, Simoa® technology has the potential to transform the landscape of oncology by offering precise and ultrasensitive measurements of cancer-related biomarkers, which may lead to earlier detection, more personalized treatment approaches, and improved patient outcomes. Download our publication brief to learn more and to view a sampling of peer-reviewed studies using Simoa® in oncology research.
Related Posts
Mapping the Tau Cascade: New Insights from p-Tau 205 and p-Tau 212 for Disease Staging and Monitoring
NPTX2: A Synaptic Biomarker of Circuit Integrity, Cognitive Resilience, and Neurodegeneration
Neurology
Advancing Translational Neuroscience with the Simoa Mammalian GFAP Assay
Publication Brief Understanding astrocyte biology is essential for advancing translational neuroscience. GFAP has emerged as a leading biomarker of CNS injury, and Simoa® technology now enables its ultra-sensitive detection directly…
Proteomics in Transition: From Discovery to Diagnostic Relevance
Proteomics is moving beyond broad discovery to deliver real-time, clinically meaningful insights. At the forefront is Quanterix’s Simoa® digital immunoassay technology, enabling ultra-sensitive, reproducible detection of low-abundance biomarkers in areas…
Neurology
Beyond Blood: Expanding Simoa Applications in Urine, Saliva, Sweat, and Tears
Publication Brief The Quanterix Simoa® platform, known for ultrasensitive detection in plasma, serum, and CSF, now delivers the same performance in alternative matrices—urine, saliva, sweat, and tears. This publication brief…
Immunology
Simoa® IL-17A Advantage PLUS: Potential Biomarker Applications in Health and Disease
App Note IL-17A is a potent pro-inflammatory cytokine that plays critical roles in inflammatory responses, host defense against infections, and tissue regeneration. This application note delves into the physiological and…
Neurology
Beyond Blood: Tear Fluid as a Window into Biomarker Discovery
While blood and CSF have long dominated biomarker research, tear fluid is emerging as a scientifically relevant, non-invasive matrix for detecting systemic and neurological biomarkers. Produced by lacrimal glands and…
Neurology
Sweat As A Non-Invasive Matrix for Cytokine Detection Using Simoa®
Inflammatory cytokines like IL-6, IL-10, and TNF-α are central to understanding aging, immune dysregulation, and chronic disease. With eccrine glands distributed across the body, sweat offers a non-invasive, physiologically relevant…